We are live on ! Find out more
6CM

683 Capital Management Portfolio holdings

AUM $1.92B
1-Year Est. Return 85.52%
This Fund
S&P 500
This Quarter Est. Return
-5.98%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$1.92B
AUM Growth
-$382M
Cap. Flow
-$115M
Cap. Flow %
-5.98%
Top 10 Hldgs %
45.28%
Holding
275
New
41
Increased
31
Reduced
101
Closed
38

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$24.8M
2
ASTH icon
Astrana Health
ASTH
+$16.6M
3
KSPI icon
Kaspi.kz JSC
KSPI
+$15.8M
4
LLY icon
Eli Lilly
LLY
+$15.2M
5
GPC icon
Genuine Parts
GPC
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 23.91%
2 Consumer Discretionary 7.8%
3 Financials 6.79%
4 Industrials 3.72%
5 Materials 3.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CACI icon
101
CACI
CACI
$10.8B
$2.18M 0.11%
4,000
-6,500
-62% -$3.91M
WW
102
WW International
WW
$133M
$2.06M 0.11%
+150,000
New +$3.36M
RNAC icon
103
Cartesian Therapeutics
RNAC
$232M
$2.03M 0.11%
330,000
+50,000
+18% +$356K
CHEC
104
Chenghe Acquisition III Co
CHEC
$2.02M 0.11%
200,000
CTMX icon
105
CytomX Therapeutics
CTMX
$705M
$2M 0.1%
+425,000
New +$2.16M
TMDX icon
106
PUT
Transmedics
TMDX
$2.5B
$1.99M 0.1%
20,000
LEGO
107
Legato Merger Corp IV
LEGO
$312M
$1.98M 0.1%
+200,000
New +$1.98M
FGII
108
FG Imperii Acquisition Corp
FGII
$288M
$1.98M 0.1%
+200,000
New +$1.98M
ARCI
109
Archimedes Tech SPAC Partners III
ARCI
$355M
$1.97M 0.1%
+200,000
New +$1.97M
AMRZ
110
Amrize Ltd
AMRZ
$27.3B
$1.96M 0.1%
35,000
VKTX icon
111
CALL
Viking Therapeutics
VKTX
$4.04B
$1.95M 0.1%
60,000
-76,500
-56% -$2.46M
STGW icon
112
Stagwell
STGW
$1.84B
$1.92M 0.1%
305,000
-525,000
-63% -$2.94M
PYPL icon
113
CALL
PayPal
PYPL
$49.5B
$1.91M 0.1%
+42,300
New +$2.04M
HDSN
114
Hudson Technologies
HDSN
$267M
$1.91M 0.1%
325,000
-10,000
-3% -$68.6K
SAIC icon
115
Saic
SAIC
$5.03B
$1.8M 0.09%
19,000
-30,000
-61% -$2.94M
ATEX icon
116
Anterix
ATEX
$1.83B
$1.76M 0.09%
+46,000
New +$1.46M
GOSS icon
117
Gossamer Bio
GOSS
$66.5M
$1.64M 0.09%
5,000,000
-190,800
-4% -$300K
PTGX icon
118
CALL
Protagonist Therapeutics
PTGX
$8.75B
$1.59M 0.08%
15,100
-35,200
-70% -$3.12M
BLUW
119
Blue Water Acquisition Corp III
BLUW
$334M
$1.54M 0.08%
150,000
CDLX icon
120
Cardlytics
CDLX
$21M
$1.52M 0.08%
145,000
+4,990
+4% +$48.7K
EVAC
121
EQV Ventures Acquisition Corp II
EVAC
$598M
$1.51M 0.08%
150,000
MAIA icon
122
MAIA Biotechnology
MAIA
$75.4M
$1.49M 0.08%
+1,066,666
New +$1.97M
ARMP icon
123
Armata Pharmaceuticals
ARMP
$171M
$1.4M 0.07%
137,000
-2,860
-2% -$24.1K
AMLX icon
124
CALL
Amylyx Pharmaceuticals
AMLX
$2.05B
$1.34M 0.07%
+96,600
New +$1.36M
PYXS icon
125
Pyxis Oncology
PYXS
$165M
$1.31M 0.07%
896,263
+4,353
+0.5% +$6.56K

Similar funds

683 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, 683 Capital Management held 275 positions worth $1.92B, down 17% from $2.3B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

683 Capital Management withdrew a net $115M in Q1 2026, closing 38 positions and reducing 101 holdings. Its most notable exit was UWM Holdings, an estimated $30.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 22% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, 683 Capital Management opened a new position in Astrana Health worth $17.2M.

  • 683 Capital Management's largest Q1 2026 buy was Astrana Health: 700,000 shares worth $17.2M.
  • 683 Capital Management added most to Becton Dickinson in Q1 2026, an estimated $24.8M increase.
  • 683 Capital Management's biggest Q1 2026 reduction was GXO Logistics, cutting an estimated $10.6M.
  • 683 Capital Management fully exited UWM Holdings in Q1 2026, selling an estimated $30.9M.
  • 683 Capital Management's ten largest holdings make up 45% of its $1.92B portfolio in Q1 2026.
  • 683 Capital Management opened 41 new positions and closed 38 in Q1 2026.
  • 683 Capital Management's portfolio value fell 17% quarter-over-quarter to $1.92B.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.